Avantor Inc.
[4 Insiders bought stock on Tuesday, 4/28/25]
Avantor Inc. [NYSE - AVTR] - $ Live Price
Avantor, Inc. is an American biotechnology, chemicals, and pharmaceutical company headquartered in Radnor, Pennsylvania.
Director Jonathan Peacock
Bought 8,091 shares
$12.81 per share
$103,646.00
Director Lan Kang
Bought 5,000 shares
$12.57 per share
$62,850.00
Director Gregory Summe
Bought 25,000 shares
$12.50 per share
$312,500.00
Director Joseph Massaro * (bought on April 29th)
Bought 8,100 shares
$12.30 per share
$99,630.00
Recent news stories during the period when INSIDERS bought their own company’s stock…
-
Insider Monkey Aproil 29th, 2025
Avantor, Inc. (NYSE:AVTR) dropped its share prices by 3.40 percent on Monday to end at $12.49 each as investors soured on its chief executive’s resignation amid the dismal earnings performance and lower outlook for the year.
According to the company, its CEO, Michael Stubblefield, is set to step down from his position as soon as the company names his replacement. He led the company’s operations for 11 years.
Stubblefield said that Avantor, Inc. (NYSE:AVTR) updated its full-year 2025 outlook “to reflect ongoing funding and policy-related headwinds,” with organic revenues now pegged to grow or drop by 1 percent year-on-year as compared with the 1 to 3 percent growth expectations previously.
Adjusted EBITDA, meanwhile, is anticipated to increase by 17.5 percent to 18 percent, a reduction from the 18 to 19 percent earlier projected.
Overall AVTR ranks 4th on our list of the worst performing stocks on Monday. While we acknowledge the potential of AVTR as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than AVTR but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
-
Investing.com April 28th, 2025
Wall Street turned bearish on Avantor (NYSE:AVTR) with Stifel and Morgan Stanley downgraded the stock to "Neutral" and "Equal-weight," respectively driven by a disappointing first-quarter performance, management changes, and emerging tariff risks.
Avantor reported a 2% decline in first-quarter organic revenue to $1.58 billion, missing Wall Street estimates, with softness across both its Lab Solutions and Bioscience Production segments.
Adjusted EPS matched consensus at $0.23, but revenue and margins fell short of expectations. The company also lowered its top-line organic growth forecast by 200 basis points.Stifel said the totality of the results and earnings call was worse than the headline numbers suggested, noting lagging growth in bioprocessing, potential market share losses, and uncertainty around pricing strategies to offset tariffs.
The brokerage lowered its price target to $14 from $19, highlighting that although Avantor remains "the cheapest stock in the group, there are too many other high-quality Tools names trading at discounted multiples to favor this one right now.Morgan Stanley similarly flagged a soft quarter and said tariff downside risk was surprisingly left out of Avantor’s updated outlook, making the stock less "ownable" in the current macro environment.
The firm said Avantor’s valuation is not demanding but warned the stock is likely to remain range-bound until better visibility emerges.Management announced that CEO Michael Stubblefield will step down once a successor is appointed, with a transition expected by February 2026.
Analysts noted that ongoing leadership changes and restructuring efforts could eventually refresh sentiment but see near-term headwinds persisting. -
Avantor, Inc. AVTR reported first-quarter 2025 adjusted earnings per share (EPS) of 23 cents, up 4.5% from the year-ago quarter. The bottom line remains in line with the Zacks Consensus Estimate. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)
GAAP EPS for the quarter was 9 cents, flat year over year.
AVTR Revenue Details
Revenues grossed $1.58 billion in the reported quarter, down 5.9% year over year. The metric missed the Zacks Consensus Estimate by 1.7%.
Avantor's foreign currency translation and Clinical Services divestiture had an unfavorable impact in the reported quarter, resulting in an organic sales decline of 2.2%.
Shares of this company plunged 16.6% till Friday’s trading.
Avantor’s Segmental Analysis
The Laboratory Solutions segment’s net sales were $1.07 billion, reflecting a reported decrease of 8% year over year. Organic sales decreased 2.9% year over year in the reported quarter. This figure compares to our segmental projection of $1.05 billion.
Per management, Avantor faced significant headwinds in its Lab Solutions segment during the first quarter of 2025, primarily caused by three key challenges. First, funding cuts in the U.S. higher education and government sectors, which account for approximately 5% of the company's total revenues, led to reduced capital spending and lower lab activity. This negatively impacted demand for equipment and consumables. Second, funding for bench-stage biotech companies plummeted by around 40%, further weakening demand from this critical customer segment. Third, heightened competitive intensity in the market resulted in volume losses at certain accounts, as customers shifted spending to alternative suppliers.
Bioscience Production’s net sales were $516.4 million, reflecting a reported decrease of 1.2%, whereas organic sales decreased 0.3% year over year. This figure compares to our segmental projection of $557 million.
Per management, Bioprocessing (representing about two-thirds of the segment) delivered low single-digit growth in the first quarter of 2025. This performance was supported by solid demand for process ingredients and excipients, as well as double-digit growth in single-use offerings like Masterflex. However, these gains were partially offset by softer demand for controlled environment consumables—critical for maintaining clean room integrity—as customers optimized usage in response to macroeconomic pressures. Despite this near-term weakness, the segment's order book remained robust, reflecting sustained momentum in bioprocessing and reinforcing confidence in a gradual recovery moving forward.
AVTR’s Margin Analysis
April 28th, 2025
In the quarter under review, Avantor’s gross profit declined 6.2% year over year to $534.9 million. The gross margin contracted 14 basis points (bps) to 33.8%. We had projected 34.3% of gross margin for the first quarter.
Selling, general and administrative expenses decreased 8.7% to $387.5 million year over year.
Adjusted operating profit totaled $242.8 million, down 6% from the prior-year quarter’s level. The adjusted operating margin in the quarter remained flat at 15.4%.
-
Investopedia - April 28th, 2025
Key Takeaways
Avantor's CEO is stepping down after 11 years as head of the chemical and other life sciences company.
The firm missed first-quarter net sales estimates as government cutbacks hurt lab solutions sales.
Avantor announced a new strategy to boost the lab sciences business, and reduced its full-year outlook.
Avantor (AVTR) shares sank 16% Friday after the maker of lab chemicals and other life sciences products announced its CEO was resigning, reported weaker-than-expected net sales as government spending fell, and slashed its guidance.
The company said the board and Michael Stubblefield agreed that this was the "right time to initiate a leadership transition." It added that Stubblefield will be stepping down as soon as his replacement is named, and that the board has already initiated the search and "plans to move through the process expeditiously." Stubblefield has led the firm since 2014.1
Avantor Posts Weaker-Than-Expected Net Sales
Separately, Avantor reported first-quarter net sales slid 6% year-over-year to $1.58 billion, missing the Visible Alpha estimate of $1.61 billion. Adjusted earnings per share (EPS) of $0.23 was in line with forecasts.2
Sales at its Laboratory Solutions division slumped 8% to $1.07 billion, which Stubblefield explained "was impacted by reduced demand—particularly in our Education and Government end market—following recent policy changes." Bioscience Production unit sales were down 1% to $516.4 million.
Stubblefield said the company was updating its full-year outlook "to reflect ongoing funding and policy-related headwinds." He added that Avantor was "implementing a comprehensive strategy to strengthen our Lab Solutions segment and are committed to moving with urgency to improve performance across the business." In addition, the company is expanding its cost-cutting plan, which is now expected to save $400 million by the end of 2027.
Avantor sees 2025 organic revenue growth in the range of minus 1% to plus 1%, compared to the previous prediction of plus 1% to plus 3%. It anticipates adjusted EBITDA margin of 17.5% to 18.5%, compared to the earlier 18.0% to 19.0%.3
Shares of Avantor plunged to their lowest level in five years.